Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Being scheduled to have elective primary minimally invasive 1 or 2 level transforaminal lumbar laminectomy interbody fusion~* ASA I, II, or III~* Informed consent form signed~Exclusion Criteria:~* Anyone weighing less than 50kg (as this would require a dosing change).~* Hypersensitivity or contraindication to intravenous acetaminophen or opioids~* Allergy to Methocarbamol; morphine sulfate, sevoflourane, or fentanyl~* Impairment of liver function-- defined as the inability to receive intravenous acetaminophen without dose adjustment as determined by the investigator; or history of chronic liver disease defined as history of hepatitis of any kind as recorded in the patient's chart~* Mental retardation recorded as a diagnosis in the patient's chart~* History of chronic pain (defined as currently receiving treatment from a specialist for pain)~* History of pain recalcitrant to intravenous morphine~* Impaired kidney function (defined as creatinine \> 1.5)~* Anyone who is not a candidate for general anesthesia or any other portion of the investigator's standard of

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- acetaminophen (Type: ACTIVE_COMPARATOR): 1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
- PlaceboComparator (Type: PLACEBO_COMPARATOR): Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).